My take on the webcast:
- They were shocked by the placebo results and cannot explain them
- they hoped for better and clear cut results
- some subgroups responded better - eg fast growing tumours
- they have 100s of pages of data to analyse, and hopeful of seeing correlations not yet noted
- all current trials are already funded
- they have many more irons in the fire
- they did not expect the shareholder response
- shareholders ‘judged a book by its cover’
MD
Ann: Immutep AIPAC Ph2b Clinical Results & Update Webcast Slides, page-12
-
- There are more pages in this discussion • 85 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
-0.005(1.41%) |
Mkt cap ! $508.4M | |||
| Open | High | Low | Value | Volume |
| 35.0¢ | 36.0¢ | 34.5¢ | $571.9K | 1.617M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 11716 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 909 | 1 |
View Market Depth
| Last trade - 15.59pm 19/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |